Prevents bronchospasm. ANDA 211600, held by Amneal Ireland. Albuterol Sulfate.
As of Nov 20, 2026, ANDA 211600 (Albuterol Sulfate), held by Amneal Ireland, was first approved by FDA on Dec 1, 2025, with 0 approved supplements and 0 published complete response letters.
Albuterol Sulfate Inhalation Aeroso is a beta 2 -adrenergic agonist indicated for: Treatment or prevention of bronchospasm in patients 4 years of age and older with reversible obstructive airway disease. Prevention of exercise-induced bronchospasm in patients 4 years of age and older. 1.1 Bronchospasm Albuterol Sulfate Inhalation Aerosol is indicated for the treatment or prevention of bronchospasm in patients 4 years of age and older with reversible obstructive airway disease. 1.2 Exercise-Induced Bronchospasm Albuterol Sulfate Inhalation Aerosol is indicated for the prevention of exercise-induced bronchospasm in patients 4 years of age and older.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Dec 1, 2025 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Albuterol SulfateEQ 0.09MG BASE/INH · aerosol, metered;inhalation | Albuterol Sulfate | Rx |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. “What FDA's review says” is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters